Introduction to Drug Safety and Pharmacovigilance
The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Collectively, these developments have not overturned the favorable benefit-risk profile of paracetamol in appropriate clinical settings. Rather, they have transformed its safety narrative from one of presumed harmlessness to one requiring the same critical pharmacovigilance applied to other used analgesics [ 43 ].”
From Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management (2026) · cites this paper as [43]
Citations
Cites
Revolutionizing healthcare: the role of artificial intelligence in clinical practice
Alowais, S. A., Alghamdi, S. S., Alsuhebany, N., Alqahtani, T., Alshaya, A. I., Almohareb, S. N., Aldairem, A., Alrashed, M., Bin Saleh, K., Badreldin, H. A., et al. (2023) · BMC Medical Education · doi:10.1186/s12909-023-04698-z · Cited by 3,146
Adverse drug reactions: definitions, diagnosis, and management
Edwards, I. R., & Aronson, J. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02799-9 · Cited by 2,979
Panagioti, M., Khan, K., Keers, R. N., Abuzour, A., Phipps, D., Kontopantelis, E., Bower, P., Campbell, S., Haneef, R., Avery, A. J., et al. (2019) · BMJ · doi:10.1136/bmj.l4185 · Cited by 874
Reeve, E., Gnjidic, D., Long, J., & Hilmer, S. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12732 · Cited by 855
Onakpoya, I. J., Heneghan, C. J., & Aronson, J. K. (2016) · BMC Medicine · doi:10.1186/s12916-016-0553-2 · Cited by 616
Swen, J. J., van der Wouden, C. H., Manson, L. E., Abdullah-Koolmees, H., Blagec, K., Blagus, T., Böhringer, S., Cambon-Thomsen, A., Cecchin, E., Cheung, K.-C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01841-4 · Cited by 556
Council for International Organizations of Medical Sciences (CIOMS)
(2025) · Cobert's Manual of Drug Safety and Pharmacovigilance · doi:10.1142/9789811297724_0006 · Cited by 543
Pirmohamed, M., Breckenridge, A. M., Kitteringham, N. R., & Park, B. K. (1998) · BMJ · doi:10.1136/bmj.316.7140.1295 · Cited by 454
Nuckols, T. K., Smith-Spangler, C., Morton, S. C., Asch, S. M., Patel, V. M., Anderson, L. J., Deichsel, E. L., & Shekelle, P. G. (2014) · Systematic Reviews · doi:10.1186/2046-4053-3-56 · Cited by 340
Clarification of Terminology in Drug Safety
Aronson, J. K., & Ferner, R. E. (2005) · Drug Safety · doi:10.2165/00002018-200528100-00003 · Cited by 328
Joining the DoTS: new approach to classifying adverse drug reactions
Aronson, J. K., & Ferner, R. E. (2003) · BMJ · doi:10.1136/bmj.327.7425.1222 · Cited by 297
Reporting of Safety Results in Published Reports of Randomized Controlled Trials
(2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.306 · Cited by 287
The Safety of Newly Approved Medicines: Do Recent Market Removals Mean There Is a Problem?
Friedman, M. A., Woodcock, J., Lumpkin, M. M., Shuren, J. E., Hass, A. E., & Thompson, L. J. (1999) · JAMA · doi:10.1001/jama.281.18.1728 · Cited by 238
Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial
Baron, J. A., Sandler, R. S., Bresalier, R. S., Lanas, A., Morton, D. G., Riddell, R., Iverson, E. R., & DeMets, D. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61490-7 · Cited by 232
Real-Time Vaccine Safety Surveillance for the Early Detection of Adverse Events
Lieu, T. A., Kulldorff, M., Davis, R. L., Lewis, E. M., Weintraub, E., Yih, K., Yin, R., Brown, J. S., & Platt, R. (2007) · Medical Care · doi:10.1097/mlr.0b013e3180616c0a · Cited by 221
De Testimonio: on the evidence for decisions about the use of therapeutic interventions
Rawlins, M. (2008) · Clinical Medicine · doi:10.7861/clinmedicine.8-6-579 · Cited by 220
The FDA Sentinel Initiative — An Evolving National Resource
Platt, R., Brown, J. S., Robb, M., McClellan, M., Ball, R., Nguyen, M. D., & Sherman, R. E. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1809643 · Cited by 216
PATHOLOGIC EFFECTS OF ELIXIR OF SULFANILAMIDE (DIETHYLENE GLYCOL) POISONING
Geiling, E. M. K. (1938) · JAMA · doi:10.1001/jama.1938.72790360005007 · Cited by 199
An historical overview over Pharmacovigilance
Fornasier, G., Francescon, S., Leone, R., & Baldo, P. (2018) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-018-0657-1 · Cited by 187
Anecdotes that provide definitive evidence
Aronson, J. K., & Hauben, M. (2006) · BMJ · doi:10.1136/bmj.39036.666389.94 · Cited by 184
The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature
Salas, M., Petracek, J., Yalamanchili, P., Aimer, O., Kasthuril, D., Dhingra, S., Junaid, T., & Bostic, T. (2022) · Pharmaceutical Medicine · doi:10.1007/s40290-022-00441-z · Cited by 181
Goldkind, L., & Laine, L. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1207 · Cited by 178
Valuing Evidence: Bias and the Evidence Hierarchy of Evidence-Based Medicine
Borgerson, K. (2009) · Perspectives in Biology and Medicine · doi:10.1353/pbm.0.0086 · Cited by 172
Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works
Santoro, A., Genov, G., Spooner, Á., Raine, J. M., & Arlett, P. R. (2017) · Drug Safety · doi:10.1007/s40264-017-0572-8 · Cited by 164
Clinical pharmacology. Adverse reactions to drugs.
Rawlins, M. D. (1981) · BMJ · doi:10.1136/bmj.282.6268.974 · Cited by 138
Scheife, R. T., Hines, L. E., Boyce, R. D., Chung, S. P., Momper, J. D., Sommer, C. D., Abernethy, D. R., Horn, J. R., Sklar, S. J., Wong, S. K., et al. (2015) · Drug Safety · doi:10.1007/s40264-014-0262-8 · Cited by 132
Patterson, R., Grammer, L. C., & Greenberger, P. A. (2017) · Cited by 126
2019 International Conference on Computational Science and Computational Intelligence (CSCI)
Diallo, O. N., Dhaussy, P., & Teodorov, C. (2019) · doi:10.1109/csci49370.2019 · Cited by 119
Seden, K., Kirkham, J. J., Kennedy, T., Lloyd, M., James, S., McManus, A., Ritchings, A., Simpson, J. M., Thornton, D., Gill, A. M., et al. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002036 · Cited by 118
ASHP guidelines on adverse drug reaction monitoring and reporting
(1995) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/52.4.417 · Cited by 113
Reumerman, M. O., Tichelaar, J., Piersma, B., Richir, M. C., & van Agtmael, M. A. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2500-y · Cited by 109
Stegenga, J. (2013) · Topoi · doi:10.1007/s11245-013-9189-4 · Cited by 106
Trifirò, G., Sultana, J., & Bate, A. (2017) · Drug Safety · doi:10.1007/s40264-017-0592-4 · Cited by 104
Self-citationPharmacovigilance in the pharmaceutical industry
Talbot, J. C. C., & Nilsson, B. S. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00713.x · Cited by 102
From Hierarchy to Network: a richer view of evidence for evidence-based medicine
Bluhm, R. (2005) · Perspectives in Biology and Medicine · doi:10.1353/pbm.2005.0082 · Cited by 99
“Artificial Intelligence” for Pharmacovigilance: Ready for Prime Time?
Ball, R., & Dal Pan, G. (2022) · Drug Safety · doi:10.1007/s40264-022-01157-4 · Cited by 95
Syrowatka, A., Song, W., Amato, M. G., Foer, D., Edrees, H., Co, Z., Kuznetsova, M., Dulgarian, S., Seger, D. L., Simona, A., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00229-6 · Cited by 94
Just a paradigm: evidence-based medicine in epistemological context
Solomon, M. (2011) · European Journal for Philosophy of Science · doi:10.1007/s13194-011-0034-6 · Cited by 81
van Eekeren, R., Rolfes, L., Koster, A. S., Magro, L., Parthasarathi, G., Ramimmy, H. A., Schutte, T., Tanaka, D., van Puijenbroek, E., & Härmark, L. (2018) · Drug Safety · doi:10.1007/s40264-018-0681-z · Cited by 80
Ongoing Challenges in Pharmacovigilance
Pan, G. J. D. (2013) · Drug Safety · doi:10.1007/s40264-013-0123-x · Cited by 75
Greenberger, P. A. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.11.002 · Cited by 74
Adverse reactions to biologic agents: Focus on autoimmune disease therapies
Lee, S. H., & Kavanaugh, A. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.03.028 · Cited by 70
CIOMS and ICH Initiatives in Pharmacovigilance and Risk Management: Overview and Implications
Tsintis, P., & Mache, E. L. (2004) · Drug Safety · doi:10.2165/00002018-200427080-00004 · Cited by 70
WHODrug: A Global, Validated and Updated Dictionary for Medicinal Information
Lagerlund, O., Strese, S., Fladvad, M., & Lindquist, M. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-020-00130-6 · Cited by 70
Roessler, M., Walther, F., Eberlein-Gonska, M., Scriba, P. C., Kuhlen, R., Schmitt, J. M., & Schoffer, O. (2022) · BMC Health Services Research · doi:10.1186/s12913-021-07414-z · Cited by 63
Spontaneous reporting—of what? Clinical concerns about drugs
Edwards, I. R. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00000.x · Cited by 62
Teaching Pharmacovigilance: the WHO-ISoP Core Elements of a Comprehensive Modular Curriculum
Beckmann, J., Hagemann, U., Bahri, P., Bate, A., Boyd, I. W., Pan, G. J. D., Edwards, B. D., Edwards, I. R., Hartigan-Go, K. Y., Lindquist, M., et al. (2014) · Drug Safety · doi:10.1007/s40264-014-0216-1 · Cited by 62
Self-citationUtilizing Advanced Technologies to Augment Pharmacovigilance Systems: Challenges and Opportunities
Lewis, D. J., & McCALLUM, J. F. (2019) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-019-00023-3 · Cited by 62
Automation Opportunities in Pharmacovigilance: An Industry Survey
Ghosh, R., Kempf, D., Pufko, A., Martinez, L. F. B., Davis, C. M., & Sethi, S. (2020) · Pharmaceutical Medicine · doi:10.1007/s40290-019-00320-0 · Cited by 62
Bahri, P. (2010) · Drug Safety · doi:10.2165/11539040-000000000-00000 · Cited by 61
An agenda for UK clinical pharmacology: Pharmacovigilance
Edwards, I. R. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04249.x · Cited by 51
Adverse drug reaction teaching in UK undergraduate medical and pharmacy programmes
Cox, A. R., Marriott, J. F., Wilson, K., & Ferner, R. E. (2004) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2003.00533.x · Cited by 51
Self-citationA global view of undergraduate education in pharmacovigilance
Hartman, J., Härmark, L., & van Puijenbroek, E. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2237-z · Cited by 48
Pharmacovigilance during the Pre-Approval Phases
Hartford, C. G., Petchel, K. Š., Mickail, H., Perez‐Gutthann, S., McHale, M., Grana, J. M., & Marquez, P. (2006) · Drug Safety · doi:10.2165/00002018-200629080-00003 · Cited by 43
Pharmacogenomics: a key component of personalized therapy
Schwab, M. G., & Schaeffeler, E. (2012) · Genome Medicine · doi:10.1186/gm394 · Cited by 41
Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance
Bate, A., Hornbuckle, K., Juhaeri, J., Motsko, S. P., & Reynolds, R. F. (2019) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098619864744 · Cited by 39
Self-citationMOdified NARanjo Causality Scale for ICSRs (MONARCSi): A Decision Support Tool for Safety Scientists
Comfort, S., Dorrell, D., Meireis, S., & Fine, J. (2018) · Drug Safety · doi:10.1007/s40264-018-0690-y · Cited by 38
Bate, A., & Stegmann, J. (2023) · Health Policy and Technology · doi:10.1016/j.hlpt.2023.100743 · Cited by 36
Self-citationAronson, J. K., & Ferner, R. E. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12706 · Cited by 35
Schutte, T., Tichelaar, J., Reumerman, M. O., van Eekeren, R., Rolfes, L., van Puijenbroek, E., Richir, M. C., & van Agtmael, M. A. (2017) · Drug Safety · doi:10.1007/s40264-016-0502-1 · Cited by 34
The Dawn of Pharmacovigilance: An Historical Perspective
van Grootheest, K. (2003) · International Journal of Pharmaceutical Medicine · doi:10.2165/00124363-200317050-00006 · Cited by 29
Schwartzberg, D. M., Ivanović, S. R., Patel, S., & Burjonrappa, S. C. (2015) · Journal of Surgical Research · doi:10.1016/j.jss.2015.03.004 · Cited by 29
Coxibs, Science, and the Public Trust
Solomon, D. H., & Avorn, J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.2.158 · Cited by 28
Comoglio, R. H. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14179 · Cited by 28
Patient Organizations’ Barriers in Pharmacovigilance and Strategies to Stimulate Their Participation
Chinchilla, K., Matos, C., Hall, V., & van Hunsel, F. P. A. M. (2020) · Drug Safety · doi:10.1007/s40264-020-00999-0 · Cited by 27
The role of pharmacogenetics and pharmacogenomics in improving translational medicine.
Dere, W. H., & Suto, T. S. (2009) · PubMed · Cited by 21
Pharmacovigilance: empowering healthcare professionals and patients
Steurbaut, S., & Hanssens, Y. I. (2014) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-014-0004-0 · Cited by 21
The future of pharmacovigilance: a personal view
Edwards, I. R. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0435-9 · Cited by 19
Mann, R. D. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1466 · Cited by 17
Prescriber compliance with black box warnings in older adult patients.
Ricci, Coulen, C., Berger, J. E., Moore, M. C., McQueen, A. L., & Jan, S. (2009) · PubMed · Cited by 17
An industry perspective on the use of machine learning in drug and vaccine safety
Painter, J. L., Kassekert, R., & Bate, A. (2023) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2023.1110498 · Cited by 17
Self-citationPerišin, A. Š., Bukić, J., Rušić, D., Leskur, D., Božić, J., Mihanovic, A., Vilović, M., Čohadžić, T., & Modun, D. (2021) · Pharmacy · doi:10.3390/pharmacy9030147 · Cited by 15
José, J., van Eekeren, R., & Jimmy, B. (2020) · International Journal of Pharmacy Practice · doi:10.1111/ijpp.12657 · Cited by 6
The Role of Pharmacoepidemiology in Industry
Gatto, N. M., Sobel, R. E., Geier, J. L., Mo, J., Bate, A., & Reynolds, R. F. (2019) · Wiley eBooks · doi:10.1002/9781119413431.ch7 · Cited by 6
Self-citationJosé, J. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620915057 · Cited by 5
Changing current practice – the prescribing of NSAIDs
Hollingsbee, D., Maskrey, N., Hutchinson, A., Underhill, J., & Bowes, A. (2011) · Prescriber · doi:10.1002/psb.795 · Cited by 3
Smith, M. J., Komparic, A., & Thompson, A. K. (2020) · Canadian Journal of Bioethics · doi:10.7202/1070232ar · Cited by 2
José, J. (2012) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/978-1-4666-0309-7.ch020 · Cited by 1
Forbes, N., Cooray, M., Al-Dabbagh, R., Yuan, Y., Tse, F., Liu, L., & Xenodemetropoulos, T. (2013) · The American Journal of Gastroenterology · doi:10.14309/00000434-201310001-01587 · Cited by 1
Research works printed but not linked: 16
- Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994. J R Coll Physicians Lond. 1995;29(1):41–9.
- Mann R, Andrew E. The Basis of pharmacovigilance: introduction. In: Mann R, Andrews E, editors. Pharmacovigilance. 2nd ed. Chichester: John Wiley and Sons Ltd; 2007. p. 3–11.
- Routledge P. 150 years of pharmacovigilance. Lancet (London, England). 1998;351(9110):1200–1. https://doi.org/10.1016/S0140-6736(98)03148. · doi:10.1016/s0140-6736(98)03148
- Stephens MD. The dawn of drug safety. Hampshire: George Mann; 2010.
- Shafique S. Thalidomide—an overview and the species-specific teratogenicity. Res J Congenit Dis. 2019;2:1.
- McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;2(1358):90927–8.
- Mohamed IN. Pharmacovigilance and reporting adverse drug reactions. Med Health. 2014;9(2):92–102.
- World Health Organization. International drug monitoring: the role of national centres. Technical report series no. 498. Geneva: WHO; 1972.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Topic E 2 A clinical safety data management: definitions and standards for expedited reporting. 1995. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf. Accessed 3 Aug 2022.
- Krska K, Cox AR. Adverse drug reactions. In: Whittlesea K, Hodson K, editors. Clinical pharmacy and therapeutics. 6th ed. Oxford: Elsevier; 2019.
- European Medicine Agency. Clinical safety data management: definitions and standards for expedited reporting. 1995. https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf.
- Dipiro CV. Obesity. In: Schwinghammer TL, Dipiro JT, Ellingrod VL, Dipiro CV, editors. Dipiro’s pharmacotherapy handbook. 12th ed. McGraw Hill; 2023. p. 657–6.
- Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006;61(8):912–20. https://doi.org/10.1111/j.1398-9995.2006.01058. · doi:10.1111/j.1398-9995.2006.01058
- Ventola CL. Big data and pharmacovigilance: data mining for adverse drug events and interactions. P T. 2018;43(6):340–51.
- Dimbil M, Kyle R, Brown JS, Aldairy W. Using real-world data for rapid safety investigations: value of near-real-time clinical data querying. Drug Saf. 2022;45(10):1251–2.
- Frontiers in Pharmacology. Pharmacoinformatics: new developments and challenges in drug design. Available at: https://www.frontiersin.org/research-topics/50433/pharmacoinformatics-new-developments-and-challenges-in-drug-design. Accessed 23 Sept 2023.
Cited by
Mantia, G. L., Marcon, G., Coppini, M., Buttacavoli, F., Panzarella, V., Colella, G., Capuano, A., Sportiello, L., Parrinello, G., Morreale, I., et al. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1572611 · Cited by 4
Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management
Nicolas, J., Leoni, M. L. G., Van Tran, Y., Van Phong, P., Farì, G., Puttini, P. S., Kaye, A. D., & Varrassi, G. (2026) · Current Pain and Headache Reports · doi:10.1007/s11916-026-01553-w
Tools and Resources for Managing Drug Interactions
Nagu, P., Thakur, A., Singh, R., & Mehta, V. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814328126010012
Metadata
- Authors
- Jose, J., Cox, A. R., & Bate, A.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- Venue
- Principles and Practice of Pharmacovigilance and Drug Safety
- Publisher
- Springer International Publishing
- Published
- 2024
- Pages
- 3-30
- OpenAlex
- W4401337825
- Cited by
- 3
- References
- 79
- Citations by year
- 2026: 2 · 2025: 1
- FWCI
- 6.02
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Springer eBooks (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- drug safety, pharmacovigilance, adverse drug reactions, spontaneous reporting, post-marketing surveillance, real-world data, clinical trial limitations, medication errors, polypharmacy, pharmacoinformatics, artificial intelligence, pharmacogenomics, drug safety regulation, history of pharmacovigilance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.